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ABSTRACT 
Guidelines specify criteria for initiation and monitoring of antiretroviral treatment (ART), 
including options for first line regimens. Immunological progress remains a widely used form of 
HIV/ART monitoring and efavirenz, a preferred first line antiretroviral drug. CD4 cell values vary 
among HIV seronegative populations and among HIV patients starting ART. Variations in 
pharmacokinetics and pharmacogenetics of efavirenz are widely documented. This thesis explores 
the role of variability in relevant baseline immunological characteristics in HIV negative and 
positive populations and how variations in the pharmacokinetics and pharmacogenetics of 
efavirenz can affect HIV/ART response in Ugandan populations. 
 
We conducted three sub-studies of HIV seronegative and seropositive Ugandans to address these 
issues. Sub-study I; Paper 1: 206 HIV seronegative Ugandans were recruited for a cross-
sectional study of variations in CD4 reference ranges. We observed a CD4 reference range of 418-
2105 cells/µL for this population, wider than ranges reported from other settings. Socio-economic 
status, altitude and prevalent tropical illnesses influenced CD4 reference values. Sub-study II; 
Paper 2:  Using records for 426 HIV infected Ugandans treated between 2002 and 2007, we 
found that patients who started therapy at low baseline CD4 cell levels were less likely to achieve 
complete immunological recovery. Sub-study III; Papers 3-6: A total of 263 HIV positive, ART 
naïve Ugandans, of which 157 were TB co-infected, were recruited and followed up to 8 months 
after starting ART. Data from these 263 patients, and from 105 healthy volunteers, were used to 
describe efavirenz pharmacokinetics for the population, and to study the effect of HIV infection, 
pharmacogenetics and antituberculous treatment on the pharmacokinetics of efavirenz. Variations 
in efavirenz pharmacokinetics were observed, and 95% of the patients reached steady state 
maximum plasma concentrations (Cmax) above the recommended range of 1-4µg/dl (3.2-12.6 
µmol/L). Efavirenz–related central nervous system (CNS) toxicity was observed in 40 (69%) of 
58 patients who were evaluated, and 38 (95%) of the patients with CNS toxicity had efavirenz 
plasma concentrations that were above the recommended range.  HIV patients displayed a 30% 
lower relative bioavailability of efavirenz compared to healthy volunteers while CYP2B6*6/*6 
genotype had lower apparent oral clearance and higher plasma concentrations of efavirenz. 
Regardless of rifampicin co-treatment, efavirenz autoinduction was prominent in CYP2B6*1/*1 
genotypes, and surprisingly, long-term efavirenz clearance was higher among patients receiving 
efavirenz-based HAART alone compared to those who were co-treated with rifampicin-based 
therapies. Population pharmacokinetic modelling of data from 99 of the HIV only patients showed 
that the efavirenz exposure was twice as high among patients homogenous for the CYP2B6*6/*6 
mutation compared to those without the mutation. It was found that a daily dose of 450 mg 
efavirenz in the general Ugandan population and a dose of 300 mg in CYP2B6*6/*6 population 
gave adequate drug exposure. 
 
Population characteristics, including immunological and genetic variations, affect the response to 
antiretroviral treatment, and population based CD4 cell values and pharmacogenetic-based dose 
modifications of antiretroviral therapies may improve HIV/ART outcomes. 
 
 
Key words: ART Outcomes, Baseline Characteristics, CD4, Efavirenz, HIV, Pharmacogenetics,  
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1. INTRODUCTION 
 
1.1. BACKGROUND ON HIV AND ANTIRETROVIRAL THERAPY 
Although HIV(human immunodeficiency virus) still poses  a major health threat worldwide with 
an estimated 34 million infected people [1], the epidemic has greatly been contained, resulting in 
reduction of HIV- related morbidity and mortality incidences. The positive shift largely followed 
introduction of antiretroviral therapy, and preventive measures that were instituted during the peak 
of the HIV epidemic. 
 
1.1.1. Effect of antiretroviral treatment on the HIV burden 
Antiretroviral therapy (ART) has been proved to improve lives of HIV infected persons [1, 2] by 
reducing HIV/AIDS-related  mortality and morbidity. An estimated 2.5 million deaths were 
averted in low and medium income countries (LMIC) between 1995 and 2010 when antiretroviral 
therapy was introduced [1]. Of these averted deaths, 1.8 million were in sub Saharan Africa, a 
region with over 69% of the estimated 34 million people living with HIV [1, 2]. The use of ART 
has also been shown to give protection to the general population by causing a reduction in the rate 
of new infections. There was an estimated 25% reduction in new infections in sub-Saharan Africa 
in 2011 (total 1.8 million new infections) compared to 2001 (2.4 million new infections) [2] and 
27% fewer infections in 2010 compared to 1996 after introduction of ART [1].  Providing 
antiretroviral prophylaxis to pregnant women living with HIV prevented over 350 000 children 
from acquiring the infection between 1995 and 2010 [1], and there was a 20% reduction in the 
mother to child transmission between 2001 and 2011 [3]. At least  85% of the children who were 
protected from HIV live in sub-Saharan Africa, a region with the highest HIV prevalence among 
women of reproductive age [1, 3]. 
 
1.1.2. Antiretroviral treatment coverage 
Antiretroviral treatment benefits spurred a progressive improvement in the access to antiretroviral 
drugs. The Global Fund and PEPFAR Fund among other donors ensured improved access of 
antiretroviral treatment to resource limited settings. In 2012, 9.7 million of the 34 million people 
living with HIV (PLWH) were estimated to be on ART in low and medium income countries [3], 
which is a six-fold increase from 2005 when only 1.3 million people were receiving ART [1]. The 
figures also represent an increase in ART coverage from 20% to 47% for low and mid income 
countries, Uganda inclusive. Figure 1 below shows a progressive increase in ART coverage 
between 2003 and 2010.
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Figure 1: Progressive increase in antiretroviral treatment coverage in low and middle 
income countries between 2003 and 2010 [1, 4] 
 
 
1.1.3. Treatment goals 
The goals of initial HIV therapy as defined by the United States Department of Health and Human 
Services guidelines include restoration and preservation of immune function; control of HIV 
replication; prevention of HIV transmission; prevention of drug resistance; reduction of HIV-
related morbidity and mortality; and improving quality of life [5, 6]. Nevertheless, regions and 
countries have not experienced the positive impact of ART in exactly the same way. Between 2005 
and 2011, AIDS-related mortality increased by 21 percent in Eastern Europe and Central Asia, and 
by 17 percent  in the Middle East and North Africa [2] while the annual number of  newly infected 
people rose from 43 000 in 2001 to 59 000 in 2010 [1, 2]. However, in Western Europe and 
Southern Africa, the mortality and number of new infections decreased over the same time period 
[1, 2]. Uganda is one of the few African countries where the incidence of HIV has continued to 
increase, with the number of new infections rising by 11 %, between 2007 and 2010 [5, 6]. Timing 
of treatment initiation is one of the major factors implicated in determining antiretroviral treatment 
success.  
 
1.2. WHEN TO START ANTIRETROVIRAL THERAPY 
Not only the access of antiretroviral treatment, but also the timing of ART initiation has proved 
to play a key role in determining therapeutic outcomes, especially in resource-limited settings 
where the question of cost-effectiveness is paramount. The debate of when to start treatment lies 
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on balancing meeting the treatments goals and reducing unnecessary costs or unwanted effects 
related to long periods on ART. 
 
Although other indicators of when to start treatment exist, CD4 T-lymphocyte cell counts are 
pivotal in defining HIV progress before and after starting treatment among adults and adolescents 
infected with HIV. T-lymphocytes are specialised white blood cells playing a central role both in 
antibody and cell-mediated  immunity[7]. The human immunodeficiency virus attacks cells 
expressing the CD4 molecule, especially the T-Lymphocytes, causing abnormalities that include 
progressive depletion and qualitative dysfunction of the CD4-T-cell population [8-10]. This forms 
the basis of the progressive immunosuppression following HIV infection and the immunological 
recovery that follows viral suppression by antiretroviral therapy. During the initial stages of HIV 
infection, the bone marrow produces and replenishes the CD4-T-cell population but there is 
progressive injury and dysfunction of the endothelial cells of the bone marrow as HIV/AIDS 
advances [11, 12]. The pathological implications of HIV infection on the CD4 T-Lymphocytes 
hence form the focus on when to start antiretroviral therapy. Treatment should start in time to 
counteract the immunosuppressive effects of the virus, and perhaps before the bone marrow loses 
its capacity to replenish the invaded cell populations. 
 
The first WHO guidelines set ART initiation when CD4 cell counts decline below 200 CD4 
cells/mm
3
 for adults and adolescents in resource limited settings [13]. This was based on the 
observation that most life threatening opportunistic infections set in with severe 
immunosuppression when CD4 cell count falls below this threshold. Other criteria included 
advanced clinical staging of HIV/AIDS irrespective of CD4 cell counts. Following research 
findings of better treatment outcomes with earlier ART initiation, there have been progressive 
shifts in guidelines for ART initiation from <200CD4 cells/mm
3
 to <250 CD4 cells/mm
3
 followed 
by <350 CD4 cells/mm
3
[13-15]. The most recent WHO guidelines recommend HAART for all 
adults and adolescents infected with HIV with CD4 cell counts ≤ 500 cells/mm³ [16]. Further, 
the guidelines recommend ART irrespective of CD4 count for HIV infected children under 5 
years of age, pregnant and breastfeeding women with HIV, HIV-positive partners in 
serodiscordant relationships and  HIV positive persons with active tuberculosis or hepatitis B 
co-infections [16]. It is evident that current thoughts for ART initiation are towards “test and 
treat”, i.e. starting all HIV positive persons on ART irrespective of their CD4 counts [13, 15-18]. 
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1.3. MONITORING ANTIRETROVIRAL TREATMENT RESPONSE 
Although the WHO and United States Department of Health and guidelines list several 
antiretroviral treatment goals, the financial implications related to the day-to-day monitoring of 
all these goals are beyond the possibilities of health systems in resource limited settings. The 
WHO recommends routine clinical and immunological monitoring of all HIV/ART patients in 
resource limited settings while other forms of monitoring, including virological and therapeutic 
drug monitoring, are reserved for cases of treatment failure and toxicity [13, 15]. This has led to 
immunological testing being the most available form of monitoring HIV/ART in resource limited 
settings, where the majority of PLWH reside.  
 
Although immunological, virological and clinical monitoring is in place, the measures and values 
used in monitoring HIV/ART progress can be influenced by several factors, and this may affect 
the interpretation of antiretroviral treatment outcomes. 
 
1.4. POPULATION VARIATIONS IN ABSOLUTE CD4 CELL COUNTS 
Despite the usefulness of the CD4 T-Lymphocytes in monitoring HIV/ART progress, absolute 
CD4 cell counts may vary within and between populations of HIV seronegative individuals. Age, 
gender, altitude, nutrition and race are among several factors that have been shown to cause CD4 
cell variations in a normal HIV seronegative population [19-32]. CD4 cell counts have been 
reported to be lower at higher altitudes and several studies have indicated higher values for 
women than men [28-30]. In addition, females have been shown to seroconvert and also reach 
AIDS at higher CD4 cell counts compared to men [33, 34], and there is some evidence that 
untreated persons with high CD4 cell counts or percentages may deteriorate faster than their 
counterparts with lower CD4 reference values [33-36]. This could have implications for treatment 
initiation. The variations caused by age seem to have the greatest challenge regarding the use of 
CD4 cells in HIV/ART management. The cell counts are highest during childhood life, declining 
slowly towards adulthood [21, 22, 26]. This has made it necessary to use CD4 cell percentages 
rather than counts in HIV managements for children below 5 years [14].  Other than HIV, other 
infections prevalent in sub-Saharan Africa can affect the immunity resulting in reduced CD4 cell 
[37-39]counts. Variations of CD4 cell counts can occur in one individual during the course of a 
day basing on level of stress, exercise or circadian cycle[40], and larger diurnal variations have 
been reported among HIV seronegative compared to seropositive individuals[41]. Despite these 
inter- and intrapopulation variations in CD4 cell reference values, similar CD4 cell reference 
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points are applied during ART initiation and monitoring. A better understanding of CD4 cell 
variations and their influence on treatment outcomes may improve HIV/ART response.  
 
1.5. THE IMPACT OF BASELINE CHARACTERISTICS ON HIV/ART OUTCOMES 
  1.5.1. The effect of the virus characteristics on HIV/ART response 
Characteristics of the Human Immunodeficiency Virus (HIV) may have direct effects on 
HIV/ART progress and therapeutic outcomes, or may indirectly affect the outcomes by interfering 
with drug disposition. While HIV type 2 is less virulent compared to HIV type 1 [42], and may 
hence cause limited immunosuppression over time, HIV-2 has been shown to have natural 
resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) [43]and certain 
polymorphisms found in the HIV-2 protease gene confer resistance to protease inhibitors which 
target HIV-1[43, 44]. Specific to HIV-1, certain subtypes were found to be more virulent in some 
populations causing faster disease progressions and death among untreated patients [45-49]. Data 
from Uganda and Kenya showed that untreated patients with HIV-1 sub-type D when compared to 
HIV-1 sub-type A, progressed faster to AIDS; had higher risk of mortality and faster rate of CD4 
cell decline [45, 46, 48]. Unfortunately, the D-subtype was shown to be the predominant type in 
the Ugandan HIV infected population [48, 50]. Retrospective data from Senegal showed that 
although sub-type A was the most predominant subtype, patients infected with HIV-1 subtypes C, 
D and G had faster progression to AIDS compared to those with sub-type A [47]. While 
implications on treatment are still under investigations, studies have shown higher frequencies of 
both reverse transcriptase and protease mutations among treated patients with HIV1 subtype D 
compared to the other clades [51, 52]. The current antiretroviral agents target different viral 
proteins essential to the lifecycle of HIV, yet the different viral types or subtypes may possess 
distinct polymorphisms that alter their interaction with specific antiretroviral drugs (ARVs) [53]. 
For this matter, variability in HIV subtype can impact on the baseline susceptibility to ARVs, and 
may in the long run affect ART response and acquisition of ARV resistance. Since most drugs 
were developed with knowledge on subtype B, which is the most circulating clade in North 
America and Europe [52, 53], there might be a knowledge gap regarding susceptibility of some 
HIV clades to these drugs.  
 
Baseline viral load (VL) been shown to affect HIV/ART outcomes. Patients with high baseline 
viral load (>100,000 copies) have poor clinical, virological and immunological success [54].  
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1.5.2. Effects of HIV/AIDS on drug disposition 
HIV/AIDS is a disease that causes physiological and anatomical damage to structures which are 
relevant in the disposition of drugs and nutrients. Altered absorption of nutrients and medicines 
has been seen in patients with HIV and the functional impairment of the absorptive surface 
worsens with HIV progress [55]. Intra-luminal bacterial overgrowth, opportunistic infection, 
HIV enteropathy and immune dysregulation are among the possible causes of histological and 
functional impairment of the GIT in HIV infected persons [55]. A higher prevalence of HIV-
infected patients with intestinal dysfunction was observed in Kampala, Uganda compared to 
London, UK [55]. Changes in acid production from parietal cells of the gastrointestinal tract have 
been observed in HIV [56] and the resultant changes in the pH can affect drug absorption. The P-
glycoprotein is a drug transporter protein that has been shown to be overexpressed in cells of 
HIV-infected compared to un-infected individuals, and can lead to increased efflux of drugs. 
This could explain the reduced accumulation of zidovudine observed in CD4-T lymphocytes 
which overexpressed the P-glycoprotein[57].  
Increased mean intestinal permeability was observed during HIV disease progress and patients 
with advanced HIV/AIDS had a three-fold increase of area under the curve (AUC) and a three-
fold decrease in oral clearance of ganciclovir[58]. Erratic absorption and low bioavailability of 
zidovudine was observed in HIV patients with lower CD4 counts [59]while a group of French 
HIV patients showed enhanced saquinavir exposure in advanced disease [60] The effect of 
HIV/AIDS status on pharmacokinetics for most of the antiretroviral agents remains to be 
explored. 
 
1.5.3. Effects of variations in CD4 cell characteristics  
Variations in CD4 cell characteristics, including quality and quantity differences, can influence 
HIV infectivity, virulence and HIV/ART response. The 32–nucleotide deletion ( 32) within the 
–chemokine receptor 5 (CCR5), a co-receptor on the CD4-receptor bearing cells, has been 
shown to confer resistance to HIV infection [61]. In order to attach to the CD4-cell receptor, HIV 
requires CXCR4 and CCR5 chemokine co-receptors which are members of the G protein-
coupled receptor [62]. The C-C chemokine receptor type 5 (CCR5) is the main co-receptor for 
the M-subtype (main HIV sub-type) during early stages of infection while the C-X-C chemokine 
Receptor type 4 (CXCR4) co-receptor is more virulent and comes into play in late stages of the 
disease [63]. There are however some cells, including the CD34(+) cells, which express both 
CD4-receptor and the CXCR4 co-receptor but remain non-permissive to infection by HIV 
following their ability to secrete high levels of CCR5-binding chemokines [64]. A recent study 
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showed that a high β-defensin genomic copy number observed in an African HIV/ART cohort 
was associated with high baseline VL and impaired immune reconstitution after 48 weeks of 
treatment with HAART [65]. β-defensins are a family of multifunctional peptides  with a role in 
inflammation, and they have been shown to bind to HIV and inhibit its replication.  These 
peptides show extensive variation in copy number of a given DNA sequence in a diploid genome 
causing alterations in their function [66]. The C868T single nucleotide polymorphism (SNP) in 
the CD4 receptor of infants born to HIV1-infceted mothers were found to have a higher risk of 
acquiring HIV compared to infants without the mutation [67]. Chemokine receptor antagonists 
including those under development differ in their comparative capacities of blocking these 
receptors, and hence patients with mainly the CXCR4 co-receptors may not benefit from 
maraviroc which is one of the available CCR5-receptor antagonists [68-70]. Further differences 
in CD4 cells have been reported to be associated with differences in latency periods of HIV 
progress and those with longer latency period giving rise to slow progressors and elite controllers 
of HIV. 
 
 1.5.4. The effect of variations in baseline CD4 cell counts  
The effect of baseline CD4 cell counts on antiretroviral treatment outcomes has previously been 
examined in ART cohorts in Europe, North America and parts of Africa [54, 71, 72]. These 
studies revealed that low baseline CD4 cell counts was independently associated with death, and 
immunological or virological failure [71, 72].  
 
Patients with advanced HIV are thought to get T-cell activation and exhaustion, and the 
microvascular endothelial compartment (MVEC) of bone marrows of patients with lower 
baseline CD4 cell counts were shown to be heavily infected with HIV compared to the MVEC in 
patients with higher CD4 counts [11, 12, 73]. These patients had a reduced capacity to respond to 
cytokine signals that augment blood cell production indicating that the hematopoietic potential 
might be compromised in patients with severe immunosuppression. Low baseline CD4 counts 
has also been associated with increase toxicity of ARVs [74], and this effect on adverse drug 
reactions is not limited to antiretroviral therapy. Research has demonstrated an increasing risk of 
drug induced hepatotoxicity with reduced CD4 cell counts [75].
 
 
 
Recent research shows reduced HIV transmission among discordant couples whose HIV infected 
partners start treatment early [76-78]. The HPTN 052 trial that followed serodiscordant couples 
from several African countries and Asia (Botswana, Brazil, India, Malawi, South Africa, 
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Zimbabwe  and Thailand) showed that providing antiretroviral therapy to the partner living with 
HIV immediately when CD4 cell count falls below 550 cells/mm
3
 was associated with a 96% 
reduction in the likelihood of HIV transmission compared to couples where ART was delayed 
until CD4  cell values fell below 250 cells/mm
3 
[78].  
 
Moreover, there is additional evidence regarding the importance of baseline HIV characteristics 
in HIV/ART progress. A study that compared CD4 T cell restoration over 1 year between 
patients with primary and those with chronic HIV showed that immune reconstitution was faster 
and more complete among subjects who commenced antiretroviral therapy during primary HIV-1 
infection[79]. A study that compared immunological and virological responses in ART naïve, 
HIV-1-infected adults at early stage of established infection (CD4>400)  with HIV seronegative 
individuals showed that increments of CD4 T cell count in blood and percentage in lymph nodes 
were comparable to HIV-negative subjects by week 24 in blood and by week 48 in lymph nodes 
[80]. CD4 cell counts have been shown to predict survival of HIV treated children, while recent 
data indicate that HIV infected individuals starting treatment with CD4 cell counts ≥500 
cells/mm
3
 would have a life expectancy comparable to that of the general population [81-84]. 
Functional cure of HIV was reported in an HIV infected child who was immediately started on 
ART instead of a conventional prevention of mother to child transmission (PMTCT) approach 
[85, 86] and in a group of 14 patients of the Visconti cohort whose treatment was started within 
10 weeks of infection [87]. 
 
Theories of presence of the latent virus and/or provirus within resting CD4 cells throw some 
hope of future approaches towards HIV cure. It is believed that HIV can stay within resting CD4 
cells as latent virus not undergoing replication, and/or as provirus which easily reverts to viral 
DNA production [88]. The average half-life of these resting CD4 cells is estimated at 44 months 
[88] and this theory provides prospective curative approaches including inducing latency of the 
virus and then eliminate the carrier CD4 cells or by controlling the provirus containing cells and 
hinder further viral DNA formation [89-91].  Suppression of productive infection has already 
been achieved in some CD4, CCR5 and CXCR4 expressing cells and in a human lymphoid cell 
line against the simian immunodeficiency virus (SIV) [91]. Other strategies include protecting 
the targeted cells (CD4 cells) and cause them to resist the infection by disrupting the CCR5 co-
receptor [92, 93]. These reports show the necessity of preserving the CD4 cells against continued 
destruction by HIV. This can be achieved by early ART initiation, and the preserved CD4 cells 
would be used in better future treatment options, including inducing latency. 
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 1.5.5. The effect of variation in other baseline characteristics 
Other baseline factors including age, gender, HAART regimen, and drug adherence affect 
antiretroviral treatment outcomes. Young age has been associated with faster immunological 
response and lower mortality [54, 74]. Although data related to effect of gender is contradicting, 
some studies have shown lower mortality and better immunological/ virological responses among 
women compared to male treated patients [94, 95]. Additionally, thrombocytopenia and 
malnutrition were reported to be associated with increased mortality among HIV treated 
patients[95].  
 
1.6. THE IMPACT OF HUMAN GENETICS ON ART OUTCOMES 
Human genetics have been associated with antiretroviral therapeutic outcomes by either having an 
effect on drug disposition or by possibly having a direct effect on certain therapeutic outcomes 
[96-99]. Immunological recovery among HIV treated patients has been related to CYP2B6 and 
UGT2B7 genotypes [96]. Increase in the mean CD4 counts after ART initiation was shown to 
continue for a longer period among CYP2B6*6 and UGT2B7*2 carriers compared to 
CYP2B6*1/*1 and UGT2B7*1/*1 carriers [96]. CYP2B6 516/983, and CYP2B6 516/CAR 
(rs2307424) genotypes were associated with efavirenz plasma concentrations, efavirenz-related 
neuropsychiatric effects and early discontinuation of efavirenz [100-103]. ABCB1-3435 C>T has 
been associated with efavirenz related risk of virological failure [104] while CYP2B6 516 was 
associated with virological success among blacks [102]. An association was reported between 
drug induced liver injury (DILI) and CYP2B6*6 genotype, NAT2 slow acetylators and ABCB1 
3435TT genotypes [99]. Although these effects could figuratively have followed high plasma 
efavirenz levels among patients of these genotypes, one of the studies did not show any 
association between efavirenz concentrations and DILI [99]. The HLA-B*5701 mutation is 
associated with increased risk of abacavir-related hypersensitivity reaction while CYP2C19 
polymorphisms predict nelfinavir plasma levels and increased risk of virological failure to 
nelfinavir [105-107].  
 
1.7. PHARMACOKINETICS AND PHARMACOGENETICS OF EFAVIRENZ  
Efvairenz has a long half-life (t1/2) of 52- 72 hours following a single dose, but the t½ is  reduced to 
40-55 hours after repeated daily dosing owing to the drug inducing its own metabolism [108]. The 
steady state is reached within 6-10 days, and at steady state Cmax concentration is 12.9 ± 3.7μmol/l, 
trough concentration (Cmin) 5.6 ± 3.2μmol/l and oral clearance of 0.18 ± 0.072L/h/kg [108, 109]. 
Efavirenz pharmacokinetics can be affected by several factors including diet, gender, genetic 
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polymorphisms and drug-drug interactions [109]. The isoenzyme Cytochrome P450, family2, sub-
family B, polypeptide 6 (CYP2B6) plays the greatest role in efavirenz metabolism, with minor 
contribution from CYP3A4 and CYP3A5, CYP1A2, CYP2A6 and CYP2C9 isoenzymes [110-
112]. The primary and major metabolite of efavirenz is 8-hydroxyefavirenz, and 7-
hydroxyefavirenz is a minor metabolite [112]. However, 8-OH efavirenz may subsequently be 
hydroxylated to 8,14-dihydroxyefavirenz [112]. At normal efavirenz concentrations, CYP2B6 
catalyses formation of both 8-hydroxyefavirenz and 8,14-dihydroxyefavirenz. CYP2C9 plays a 
minor role in formation of the 8,14-dihydroxyefavirenz, while other isoforms only catalyse the 
formation of 8-hydroxyefavirenz [112]. Among these enzymes, the catalytic potential is highest to 
lowest in CYP2B6, CYP3A5, CYP3A4, and CYP1A2, respectively. However, at very high 
efavirenz concentrations, CYP2A6, and CYP2C9 contribute to the formation of 8-
hydroxyefavirenz in addition to CYP2B6, CYP3A5, CYP1A2, CYP3A4 [112]. CYP2A6 and 
CYP3A4 have shown prominence in efavirenz clearance when CYP2B6 is impaired [113]. 
UGT2B7 is also involved in efavirenz metabolism while ABCB1, a gene that encodes P-
glycoprotein plays a role in efavirenz disposition. 
 
CYP2B6 is primarily expressed in the liver where it contributes 1-10% of the total P450 enzymes, 
and with an inter-individual variability of up to 100 fold in the degree of protein expression and/or 
activity [114, 115]. The inter- and intraindividual variability in the protein expression and activity  
of the hepatic CYP2B is attributed to several factors including environment, age, gender, genetic 
polymorphisms, and induction or inhibition by other compounds. Regarding the genetic causes, 
single nucleotide polymorphisms (SNPs) cause variations in protein expression and enzymatic 
activities. The SNP c.516 G>T in the allele CYP2B6*6 has been associated with approximately 
50–75% decreased protein level [116], and human liver microsome samples (HLM) of persons 
homozygous for the CYP2B6*6 polymorphism showed a 2-fold lower catalytic activity for 
efavirenz compared to the wild type [117]. Six polymorphic variants (CYP2B6.4 to CYP2B6.9) 
were shown to be alternatively expressed; CYP2B6*5 and *7 having increased metabolic activity 
compared to the wild type, CYP2B6* and *9 having reduced activity, while *8 had no activity for 
efavirenz [116]. Efavirenz pharmacokinetics is predicted by CYP2B6 polymorphisms: The (516G -
-> T and 983T --> C) polymorphisms being associated with low efavirenz clearance and high 
plasma concentrations [118-122], efavirenz toxicity, and early drug discontinuations [75, 102, 103, 
123, 124]. Other low activity CYP2B6 alleles, including *11, *18, *27, *28, also predict high 
efavirenz plasma levels [102, 115, 119].  Five new variants CYP2B6*33, *34, *35, *36 and *37 
were recently identified in a cohort of Rwandese HIV-1-infected patients and CYP2B6*33, *34, 
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*35 and *36 were shown to result in complete or almost complete loss of CYP2B6 metabolism of 
efavirenz [115, 125] .  
 
Ethnic differences exist in protein expression and activity of the CYP450 metabolising enzymes. 
CYP2B6*6 has been  reported at frequencies of 15 to over 60% [115]; Asians at 10-21%, 
Caucasians at 14-27%, Africans at 33-50% and Papua New Guineans at 62%. Among the African 
population, CYP2B6*6 was found to be more frequent in Southern Africa (Zimbabwe and South 
Africa) compared to Eastern Africa (Uganda and Tanzania), and even within the Ugandan 
population, the frequency was higher among the persons of the Nilotics origin compared to Bantu 
group [126]. CYP2B6*18 (c.983C>T [I328T]) is currently thought to be the second most 
functionally deficient allele occurring at allele frequencies of 4–11% in African subjects [115, 
127]. The polymorphisms are related to the racial differences in efavirenz pharmacokinetics and 
pharmacodynamics, and consequently, Caucasians have been shown to have higher clearance of 
efavirenz and nevirapine compared to persons of African and Asian origin [111, 128].  
 
HIV/ART treated patients who are homozygous for CYP2B6*6 polymorphism were shown to have 
long term increase in C4 cell counts compared to the CYP2B6*1/*1[96] and Tanzanian treated 
patients had better increase in CD4 cell counts attributable to a higher prevalence of CYP2B6*6/*6 
among Tanzanians compared to Ethiopians[129]. Sex differences in liver expression of the 
CYP450 activity have been observed with females’ liver donors showing a higher expression and 
activity of CYP2B6 [115]. Women have also been shown to have higher CYP3A family isoform 
activity compared to men [57, 65]. However, these sex difference in CYP2B6 and 3A4 expression/ 
activity does not match the elevated efavirenz plasma concentrations in females due to a large 
volume of distribution in females compared to males [122, 130].  
 
There is a high variability in the metabolic activity of the CYP3A family with a 40-50 fold 
difference across populations [54]. Regarding CYP3A5 polymorphisms, CYP3A5*3 is most 
common in all ethnic groups at a prevalence of 90-93% among Caucasians, 65% in Hispanics, 60% 
in South Asia and 32% among African Americans [56, 57]. Although the CYP3A5*3 
polymorphism is more prevalent in Caucasians compared to Africans, CYP3A family activity is 
lower in persons of African ancestry compared with Caucasians [53]. CYP3A5*6 and *7 are 
associated with reduced CYP3A5 activity, and were identified at frequencies of 10-22% among 
Africans but rare or nearly absent in the white population [131, 132]. Other identified CYP3A 
isoforms causing racial differences include CYP3A4*1B polymorphism occurring in Caucasians at 
a frequency of 9.3 - 11%, at 2 - 9.6% among Hispanic Americans, and 35 - 67% among African 
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Americans. Another candidate polymorphism that may explain differential CYP450 activity in 
different racial/ethnic groups is the recently identified CYP3A4*20 with no activity [53]. This 
recently identified SNP has a relatively high prevalence amongst differing ethnic groups: 
Caucasians (6%), African Americans (26%) and Chinese (22%). CYP3A4*22 is another newly 
identified SNP in intron 6 of CYP3A4 which showed lower expression in vitro [63]. Carriage of 
the CYP3A4*22 polymorphism has been associated with lower necessary statin doses and 
enhanced simvastatin-mediated cholesterol reduction in carriers (allele frequencies 4.3, 4.3 and 
8.3% for African Americans, Chinese and Caucasians, respectively). 
 
In the liver, Cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of several drugs 
including antiretroviral agents efavirenz and nevirapine; antimalarial agents including artemisinin; 
but also other agents including bupropion, cyclophosphamide, ketamine and methadone. Other 
than the liver, CYP2B6 has been identified in several organs/systems including the lungs, bronchial 
tree and nasal mucosa; in the gastrointestinal tract, including colon and luminal lining of the 
intestinal cells; the skin; brain and the kidneys [133]. Functions in such organs include 
detoxification of toxins and pesticides at the skin and lung surface biotransformation of centrally 
acting agents. CYP3A4 is most abundant liver isoform, representing up to 50% of hepatic CYP450, 
while CYP3A5 only represents around 2% of the total liver CYP3A [134].  The CYP3A enzymes 
have also been identified in human gastrointestinal tract including the small intestines, oesophagus 
and colon where they are involved in the biotransformation of several carcinogenic compounds, 
and metabolism of some drugs[135].  
 
 
1.8. PHARMACOGENETICS INFLUENCE ON EFAVIRENZ DRUG INTERACTIONS 
Efavirenz interacts with other drugs causing changes in pharmacokinetic parameters of either 
efavirenz itself or the other drugs in the combination. Among the drugs that form important 
interactions with efavirenz are other antiretroviral agents, antituberculous drugs, antimalarial 
agents and drugs used against hepatitis. Efavirenz interacts with ritonavir darunavir, nelfinavir 
causing reduction in their AUC and/or plasma concentrations [136-138]. The fatality and 
proportion of HIV patients co-infected with tuberculosis in Sub-Saharan Africa, has called much 
attention to interactions between efavirenz and anti-tuberculosis drugs especially rifampicin. 
Efavirenz may cause reduction in plasma concentrations of rifampicin by inducing the CYP450 
metabolising enzymes. Likewise through the induction of the CYP450 enzymes that metabolise 
efavirenz, rifampicin has been shown to increase the clearance of efavirenz concentrations 
hence lowering its concentrations [128]. For this reason, WHO proposed an adjustment in 
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efavirenz dosage from 600 to 800mg for patients who are above 50kg and are co-treated with 
rifampicin [15].  
 
Most of the above drug-drug interactions act via CYP450 enzyme induction or inhibition. 
Rifampicin induces both CYP2B6 and CYP3A and even the CYP2A6 isoforms of the CYP450 
enzymes resulting in increased metabolism of efavirenz. Rifampicin also induces ABCB1 which 
encodes P-glycoprotein, which is also involved in efavirenz disposition. However, recent 
findings have proposed a counter effect of other anti tuberculosis drugs. Rifampicin is usually 
given in combination with isoniazid, pyrazinamide and ethambutol, and with the exception of 
ethambutol, the other anti tuberculosis drugs are reported to have varying effects on the 
enzymes involved in efavirenz metabolism [139, 140]. The 7-hydroxylation of EFV among 
persons with CYP2B6*1/*1 genotype was reported to be inhibited by isoniazid, rifampicin and 
pyrazinamide. Isoniazid has the greatest inhibiting effect, including the inhibition of CYP2A6 
and CYP3A4 enzymes whose activity increase at high efavirenz concentrations as those that 
occur in CYP2B6 slow metabolisers [139, 140] (Figure 2). Despite previous fears of reduced 
efavirenz exposure during rifampicin co-administration, several studies have failed to 
demonstrate this effect while others demonstrated a paradoxical increase in efavirenz levels 
during antituberculous treatment [115, 141-143]. 
 
In addition to antituberculous drugs, efavirenz interacts with other drugs of importance to HIV 
burdened regions. Lower concentrations of artemether and lumefantrine have been detected 
among children treated with efavirenz [144] compared to those on lopinavir [144, 145], and 
subsequent poor treatment outcomes have been observed among efavirenz co-treated malaria 
patients compared to those co-treated with lopinavir [146]. These findings regarding 
antimalarial drugs presents efavirenz as a possible hindrance to malaria treatment while the six 
months treatment period with anti tuberculosis drugs is a challenge to both antiretroviral and the 
anti tuberculosis treatment outcomes. HIV-Hepatitis co-infection is also common, and efavirenz 
may lower the AUC of boceprevir and telaprevir which are forthcoming protease inhibitors 
against hepatitis C [147, 148]. 
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Figure 2: Diagrammatic representation efavirenz metabolism in the liver cells and the effect of anti 
tuberculosis drugs interactions [112, 139, 140]: CYP2B6 is the main enzyme that catalyses efavirenz 
metabolism with contributions from CYP3A4/5, CYP2A6, CYP2C9 and CYP1A2. Rifampicin (RH) enhances 
efavirenz metabolism while isoniazid (INH) and pyrazinamide(PZ)  inhibits the metabolism. 
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2. RATIONALE  
 
In resource limited settings, monitoring of HIV/ART usually relies on clinical and immunological 
staging.  However, patients initiating treatment at the same disease staging and on the same 
HAART regimen may have varied therapeutic outcomes. Patients’ baseline characteristics 
including disease staging, gender, age, and genetic differences may influence treatment outcomes 
including occurrence of adverse drug reactions. The influence by these additional factors may be 
through interference with the pharmacokinetics of the drug or through factors not yet well defined. 
Baseline CD4 cell characteristics including absolute numbers, are associated with HIV infectivity, 
ART response, and drug induced toxicity. On the other hand, pharmacogenetic variability is 
associated with efavirenz levels, toxicity, and treatment outcomes. The extent and role of 
variability of the genetics and baseline characteristics need much exploration in regions with high 
HIV burden.   
 
This thesis describes variations in relevant baseline characteristics, and the effect these differences 
may have on the antiretroviral treatment outcomes. It also discusses pharmacogenetic variations 
that are relevant to HIV/ART therapy and their impact on treatment outcomes.   
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3. OBJECTIVES OF THIS WORK 
3.1. GENERAL OBJECTIVE 
The general objective of this thesis was to examine variations in baseline characteristics, 
pharmacokinetics and pharmacogenetics of antiretroviral drugs, and study their possible impact on 
HIV/ART outcomes.  
 
 
3.2. SPECIFIC OBJECTIVES 
3.2.1. To establish CD4 references as an HIV/AIDS baseline characteristic,  and study 
their variations in the Ugandan population (Paper 1) 
 
3.2.2. To examine the effect of baseline HIV/AIDS characteristics on selected ART 
outcome measures in Uganda (Paper 2) 
 
3.2.3. To investigate the effect of HIV/AIDS on the pharmacokinetics of efavirenz in the 
Ugandan population (Paper 3) 
 
3.2.4. To study variations in pharmacokinetics of efavirenz and their possible impact on 
therapeutic outcomes in the Ugandan population (Paper 4) 
 
3.2.5.  To study variations in pharmacogenetics of efavirenz and their possible impact on 
therapeutic outcomes in the Ugandan population (Papers 5 and 6) 
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4. MATERIALS AND METHODS 
 
4.1. STUDY DESIGN 
Three studies were conducted to address the objectives of this thesis. A cross-sectional study 
among healthy volunteers was carried out to investigate CD4 reference range variations (Sub-
study I;  paper 1), while retrospective data collected during routine HIV/ART care were used for 
the second objective (Sub-study II; paper 2).  Objectives 3-5 were answered using a prospective 
study of patients with HIV infection, including those with and without TB co-infection (Sub-study 
III; Papers 3-6)).   These prospective patients’ data were either analysed as data from HIV 
infected persons only (papers 4 and 5); or combined with published data on healthy volunteers 
(papers 3); or combined with TB co-infected patients’ data (paper 6). The general methodology 
is displayed in figure 3. 
 
 
Figure 3: General methodology of the design and participants used in investigating the 
variations in HIV baseline characteristics, pharmacokinetics and pharmacogenetics of 
antiretroviral drugs, and their impact on ART treatment outcomes 
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4.2. STUDY AREA AND POPULATION 
The study was conducted at four sites selected in two regions of the country; two in the central 
and two in south-western regions of Uganda (fig.4). It was anticipated that the two regions vary in 
socio-demographics and perhaps genetically. The sites in central Uganda were Mulago and 
Butabika hospitals, both of which are in Kampala district, and the sites from western Uganda were 
Mbarara hospital and Bwera hospital in Mbarara District and Kasese Districts, respectively. 
Topographically, Kampala (central Ugandan region) lies at a relatively low altitude of about 
914m ASL, compared to western Uganda region which includes the Rwenzori mountains 
reaching 5113 meters above sea level[149]. Kampala District is 238 square kilometres, more 
industrialised and populated compared to western Uganda[150]. It is estimated that 15 percent 
of the population in Kampala live below the poverty line while 30 percent of the population in 
western Uganda live below the poverty line[150]. Although both regions are inhabited by 
people of Bantu origin, slight differences occur in appearances, language, culture and practices, 
giving a possibility of slight genetic differences. The site selection was designed to capture 
possible in-country differences in socio-demographics and genetics. Sub-studies I (paper 1) and II 
(paper 2) were conducted in Kampala and Mbarara Districts while participants for sub-study III 
were recruited from Kampala and Kasese Districts. Figure 4 presents the study sites. 
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Figure 4: Study sites for investigating the variations in HIV baseline characteristics, 
pharmacokinetics and pharmacogenetics of antiretroviral drugs, and their impact on ART 
treatment outcomes. The areas highlighted with yellow above represent the three districts where patients were 
recruited for the study; from smallest to largest are Kampala, Kasese and Mbarara Districts, respectively. 
 
 
4.3. PATIENTS’ SELECTION AND MANAGEMENT 
Study participants included 206 healthy volunteers for CD4 reference range establishment and 
HIV infected patients, 263 before and 426 after initiating treatment for pharmacokinetics and ART 
outcome studies, respectively.  The effect of HIV/AIDS and pharmacogenetics on the 
pharmacokinetics of key antiretroviral drugs was studied using HIV-infected patients, HIV/TB co-
infected patients and data from healthy volunteers. For the healthy volunteer study, sensitization 
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was done within communities around the study sites and volunteers who came to the study sites 
were screened for potential participation. On the other hand, HIV positive patients who were 
considered ready for ART initiation were screened for possible participation in the 
pharmacokinetic/pharmacogenetic studies. Healthy volunteers for the CD4 cell study were 
counselled and their physical status checked prior to having early morning blood drawn for both 
HIV testing and C4/CD8 cell establishment while HIV positive ART naïve patients used in the 
pharmacokinetic studies were admitted overnight for intensive sampling on days 1 and 14 of 
treatment, and then followed in the out-patient department for sparse sampling over 8 months. All 
HIV patients were started on 600mg efavirenz combined with 300 mg zidovudine and 150mg 
lamivudine in daily doses. The TB co-infected patients in Paper 6 were concurrently treated with 
rifampicin, isoniazid, pyrazinamide and ethambutol for two months followed by rifampicin and 
isoniazid for 4 months (2RHZE+4RH). Tuberculosis treatment for these patients was initiated 2 
weeks prior to antiretroviral therapy. All patients were concurrently taking 960mg of 
cotrimoxazole daily as chemoprophlaxis for pnuemocystis Jerovani pneumonia. Studying 
therapeutic outcomes needed a follow-up period that was longer than what was feasible for this 
work. Therefore, retrospective data was retrieved from files of HIV/ART patients who had been 
treated for 1-5 years (sub-study 2).  
 
4.4. PROCEDURES FOR SAMPLE COLLECTION AND ANALYSIS 
4.4.1. Blood sample collection and processing 
Blood samples were collected to perform HIV serology testing, haematological values including 
CD4/CD8 cells, HIV1 RNA tests, efavirenz plasma concentrations and genotyping for CYP2B6 
(*6 and *11), CYP3A5 (*3,*6 and*7) and ABCB1 (rs3842 and 3435C>T). For sub-study I; two 
blood samples, each 5 mL, were drawn from each participant through antecubital venous puncture 
using a Vacutainer (BD, Franklin Lakes, NJ) needle. One of the samples was collected in a 5 mL 
SST Gel and Clot Activator Vacutainer for HIV testing, and the second sample in a 5 mL EDTA-
containing Vacutainer for determination of hematological indices. HIV tests were performed using 
a commercially available enzyme immunoassay kit (Welcozyme HIV-1 and -2 kit, Murex 
Diagnostics, Dartford, England), and discordant samples were confirmed using the Recombigen 
(env and gag) HIV-1 assay kit (Cambridge Biotech, Dartford, England). Samples for 
haematological tests were collected between 8 am to 11 am and analyzed within 4 hours using the 
PanLeucogating protocol. 
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Samples for determination of efavirenz plasma concentrations (sub-study3) were collected at 9 
time-points over 24hour on days 1 and 14 for 66 ART naïve HIV patients, and then between 11-
24hours over 8 months, for these and additional  197 HIV infected patients (157 HIV/TB co-
infected).  Four (4mL) of whole blood was drawn using an antecubital cannula and immediately 
centrifuged at 3000 rpm (1560 g) for 10 min. The plasma was stored at 
_
70 1C until it was 
transported to Sweden for analysis using high-performance liquid chromatography (HPLC). 
Whole blood equivalent to 10mls were collected from each patient at enrolment and using this 
sample, genomic DNA was isolated from peripheral blood leukocytes using QIAamp DNA Maxi 
Kit (QIAGEN GmbH, Hilden, Germany). Additionally, 10mls of blood for CD4 counts and HIV-
RNA measures were collected at baseline and after every 3 months.  
 
4.4.2. CD4/CD8 estimation  
CD4/CD8 T lymphocytes and other haematological indices were performed on 206 HIV 
seronegative Ugandans.  CD4/CD8 analysis was done using a double platform PanLeucogating 
method on an Epics XL-MCL Beckman Coulter flow cytometer (Beckman Coulter, Miami, FL). 
Using  two MCL Epics XL tubes (Beckman Coulter), 10 µL of the PLG CD4 monoclonal 
antibodies (CD4 and CD45) was added to either of the tubes, and 10 µL of the PLG CD8 
monoclonal antibody to the second tube.  One hundred µL of well-mixed blood samples were 
pipetted into each of the tubes containing the monoclonal antibodies, gently vortexed, and 
incubated at 20°C-25°C in the dark for 10 minutes before 800 µL of the lyse was added. The 
mixture was further incubated at 20°C-25°C for 15 minutes, after which the tubes were loaded 
into the cytometer for analysis. 
 
4.4.3. Efavirenz plasma level quantification 
Blood samples drawn for the pharmacokinetic studies were immediately centrifuged at 3000 
rpm (1560 g) for 10 min; plasma was stored at 70
0
C until the time of efavirenz quantification 
using High-performance liquid chromatography (HPLC) analysis. HPLC analysis was carried 
out at the Department of Laboratory Medicine, Karolinska University Hospital Huddinge 
(Karolinska Institute, Stockholm, Sweden), where reverse-phase HPLC with UV detection was 
used to determine the plasma efavirenz concentration. For HPLC, an Agilent Series 1100 
(Agilent Technologies, Santa Clara, CA, USA), consisting of column compartment G1316A, 
degasser G132A, Quat pump G1311A, auto-sampler G1329A ALS, and diode array detector 
G1315B was used. The column used was Ace3C18, 3 mm, 50 _ 30mm (Advanced 
Chromatography Technologies, Aberdeen, UK) and the mobile phase consisted of 30% 
acetonitrile, 30% methanol, 4 mmol/L potassium hydroxide and 10 mmol/L acetic acid (pH 4.3). 
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Plasma proteins were precipitated with acetonitrile before centrifuging, after which 6 mL of the 
supernatant was injected and eluted at 0.80 mL/min for 3.5 min. The reference material was 
99.9% efavirenz supplied by the WHO Collaborating Center for Chemical Reference 
Substances through Apoteket AB (Stockholm, Sweden), and the retention time was 2.42min as 
detected at UV-VIS 1, 210nm, UV-VIS 2, 220 nm. This method was linear, and the within-day 
coefficient of variation was 3.2, 3.3 and 5.1% at concentrations of 0.63 (n517), 2.53 (n517) and 
6.31mg/L (n516), respectively, with a between-day coefficient of variation of 4.1% (n550) and a 
limit of quantification of 0.11mg/L.  
 
4.4.4. Genotyping 
Genomic DNA was isolated from peripheral blood leucocytes using a QIA amp DNA Maxi kit 
(Qiagen GmbH Hilden, German). Only SNPs that had were previously identified to be of clinical 
importance, including CYP2B6 (*6 and *11), CYP3A5 (*3,*6 and*7) and ABCB1 (rs3842 and 
3435C>T) were determined on patient genomic DNA using the TaqMan method. Allelic 
discrimination reactions were performed using TaqMan (Applied Biosystems, CA, USA) 
genotyping assays: (C___7586657_20 for ABCB1 3435C>T, C___7817765_60, for ABCB1 
rs3842T>C, C__29560333_20, for CYPB6 516G>T [CYP2B6*6 ], for CYP2B6 136A>G 
[CYP2B6*11], C__26201809_30 for CYP3A5 6986A>G [CYP3A5*3], C__30203950_10 for 
CYP3A5 14690G>A [CYP3A5*6]) and C__32287188_10 for CYP3A5 g.27131_27132insT 
[CYP3A5*7] on ABI 7500 FAST (Applied Biosystems, Foster City, CA). The final volume for 
each reaction was 10μl, consisting of 2x TaqMan Universal PCR Master Mix (Applied 
Biosystems), 20 X drug metabolising genotype assay mix and 10ng genomic DNA. The PCR 
profile consisted of an initial step at 50
o
C for 2 min and 50 cycles with 95
o
C for 10 minutes and 
92
o
C for 15 minutes. 
 
4.5. DATA MANAGEMENT, ANALYSIS AND MODELLING 
For sub-study 1 (paper1), data were collected directly from patients using pre-tested data 
collection tools while clinical data for sub-studies II and III were collected from patient clinical 
files. All data were entered into excel files (sub-study 1), and Epi-info (sub-studies II and III). 
Also, electronic data, including pharmacokinetics, and pharmacogenetics analyses were extracted 
and entered into excel sheets. Double entries were made, followed by data cleaning prior to export 
into different softwares for analysis. Stata, Statistica and SPSS softwares were employed to 
calculate and compare means, medians and incidence rates that are reported in papers 1 and 2. 
WINOLIN software was employed for non-compartmental analysis (NCA) in paper 4, while 
NONMEM was used for population pharmacokinetics (PPK) analysis in papers 3, 5 and 6. The 
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effect of HIV/AIDS, pharmacogenetics, gender and other biological variables were tested by 
covariate analysis using a forward-selection (α=0.05) followed by backward elimination (α=0.01) 
method.  
 
In paper 3; efavirenz pharmacogenetics and pharmacokinetic data for samples collected over 24 
hours following the first dose of 600mg efavirenz based HAART were compared with published 
results from HIV seronegative Ugandans [130]. Population pharmacokinetic models were fitted to 
the data, using NONMEM VI software. The first-order conditional estimation method with 
interaction was used to describe the data.   In paper 5; Pharmacokinetics data (556 steady-state 
plasma efavirenz concentrations collected over 5 different times per patient between 11-18hrs 
after dose) and pharmacogenetics data ((CYP2B6 (*6 & *11), CYP3A5 (*3,*6 & *7) and ABCB1 
(c.4046A>G) for 99 (64 female) were simulated based on the AUC for the efavirenz 600 mg 
product label. A one-compartment population pharmacokinetic model with first-order absorption 
was used to estimate the genotype effects on EFV pharmacokinetics. Doses of 300, 450, and 600 
mg were simulated for each of the six possible CYP2B6*6 and ABCB1 (c.4046A>G) 
combinations.  In paper 6; sparse pharmacokinetics data collected over 8 months and 
pharmacogenetics data (CYP2B6 (*6 & *11), CYP3A5 (*3, *6 & *7) and ABCB1 (c4036A>G & 
c.3435C>T)) from ART naïve HIV patients (157 with and 106 without TB) were analysed. 
Efavirenz apparent oral clearance was determined on days 14, 56, 84 112, 140, 168, 196 and 224 
and compared between the HIV only and HIV/TB co-infected group. The effect of covariates 
including genotypes, rifampicin, biochemistriy data and demographic factors on apparent oral 
clearance of efavirenz at the different time points was assessed by Kruskal Wallis analysis of 
variance (ANOVA) using Statistica version 10 (StatSoft Inc., Tulsa, OK, USA). Graph Pad Prism 
version 5.0 for Windows (Graph Pad, La Jolla, CA, USA) was used for graphical presentation. p< 
0.05 was considered as significant 
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Fig. 5: Effect of recent acute illnesses on CD4 
cell counts of HIV Seronegative Ugandans 
5. RESULTS 
 
 
5.1. VARIATION IN ABSOLUTE CD4 CELL REFERENCE VALUES FOR THE 
UGANDAN POPULATION; PAPER 1  
 
The Ugandan HIV seronegative population displayed a great variability in absolute CD4 cell 
counts. A sample of 172 healthy volunteers had an absolute CD4 cell reference range of 418-
2105 cells/µl, which is wider than the reference range 500-1500 cell/µl considered worldwide.  
During this study, absolute CD4 cell values were found to be affected by factors that included 
recent ailments, altitude and socio-economic status. Although 206 volunteers were enrolled as 
healthy participants at the time of the study, 34 (16.5%) of them had suffered recent infections 
that needed medical attention, and their mean CD4 cell value was lower than that of their 
healthy counterparts; 783 (CI 776-789) and 992 (CI 957-1026) cells/µl respectively (Fig. 5).  
For this reason, the results of the 34 volunteers were not included in the calculation of the 
country’s reference ranges.  
 
About 25% of the studied population had a median income of $15/ month, indicating that they 
were living below the poverty line (less than 1 dollar/ day), another approximated 25% had a 
median monthly income of $35 while the median monthly income of the 47.1% was $100. Data 
on monthly income was not available for 10 of the volunteers. Participants living on <$1/day 
had a statistically significantly lower mean CD4 cell count that their counterparts (p=0.001) 
(Table 1). 
  Table 1: Effect of Socio-economic Status on       
   CD4 Cell Counts of Seronegative Ugandans 
 
Socioeconomic category  Mean CD4 (CI) 
(p value)  
Lowest (23.3%) 
 ($15)  
773 (675-872)   
(Ref)      
Middle (23.5..%) 
($35 )  
1044 (926-1162)   
(p=0.001)      
Highest  (47.1%) 
  ($100)  
1125 (1039-1211) 
(p=0.001)     
Fig. 3 shows a comparison in mean CD4 cell counts between healthy 
volunteers (category 3) and volunteers with recent ailments that 
needed medication (category 1). The mean CD4 cell count for health 
volunteers was higher for that for participants without recent ailments 
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About 38% of the participants were recruited from Mbarara district while the remaining 62% 
were from Kampala. The mean CD4 cell count for Mbarara participants; 742 (667-824) was 
lower than that of Kampala participants 1082 (1017-1151) (Fig. 6).  
 
 
 
 
 
 
Figure 6: Effect of altitude on CD4 cell counts in HIV seronegative Ugandans  
Kampala District, located in central Uganda is more industrialised and more populated while Mbarara District 
which is located in western Uganda is less industrialised, sparsely populated, and characterised by hills and 
mountains. Mean CD4 cell counts were higher for health volunteers from Kampala District.  
 
 
 
5.2. THE EFFECT OF VARIATION IN BASELINE CHARACTERISTICS ON ART 
OUTCOMES IN UGANDA; PAPER 2 
 
Despite the fact that WHO and national guidelines recommended commencement of ART at 
CD4 cell counts < 200 cell/µl, results from retrospective data collected over time from two 
HIV/ART centres in Ugandan showed a great variation in absolute CD4 cell counts both at 
baseline and during the course of treatment. The median baseline CD4 cell value was 109 
cells/µl (IQR 41-184) with 27.5% of the population initiating treatment below 50 CD4 cells/µl. 
Owing to deterioration in WHO/CDC clinical stage to III or IV, 20.7% of the studied population 
were started on antiretroviral therapy before their absolute CD4 cell counts dropped below 200 
cells/µl and above. During a follow-up period of 1061.1 personal years on HAART, the overall 
rate and extent of immunological recovery differed by time, baseline CD4 cell count, gender 
and site.  
 
 
Mean 
(95% CI) 
Kampala 
(n=107)  
Mbarara 
(n=65)  
CD4 
(cell/µl) 
1082  
(1017-1151)  
742 
(667-824)  
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5.2.1. Effect of baseline CD4 cell count on immunological recovery 
Using the reference range from sub study I, reported in paper 1 (418 – 2105 cells/µl) to define 
immunological recovery, we examined the effect of baseline absolute CD4 cell counts on 
immunological recovery for this population. Overall, 37.1% of the patients attained the target 
CD4 count of 418cells/µl; and the median baseline CD4 count for this group of patients was 142 
cells/µl (IQR 72-212) while the median baseline CD4 count for the 62.9% non-recovering 
population was 86 cells/µL (IQR 34-155). Analysis based on baseline CD4 levels of 50, 100, 
200 and 250 cells/µL showed a positive correlation between baseline CD4 counts and 
immunological recovery (Table 2). Patients with baseline CD4 counts of >100 cells/µl reached 
the targeted 418 CD4 count 2.16 times faster than the patients who initiated treatment below 
100 cells/µl while patients of baseline CD4 count ≥ 200cells/µl reached the target 1.89 times 
faster than patients who initiated ART below 200 CD4 counts. Other than its effect on 
immunological recovery these data also demonstrated reduced incidence rates of new infections 
with increasing baseline CD4 count. 
 
Table 2: Incidence rates of reaching 418 CD4 cells/µl among HIV infected Ugandans who 
initiated HAART at different CD4 counts  
Baseline CD4 
Category 
n Incidences of 
attaining  418 
CD4 cells/µL 
Incidence rate/ 
1000 years 
Rate ratio 
≥250 30 15 284 (143-445)  
1.49 0 -  249 396 143 191(152-230) 
     
≥ 200 88 43 329 (231-427) 1.89 
 0 - 199 338 115 174(134-214) 
     
≥100 231 107 274 (217-332) 2.16 
0 - 99 195 51 127(80-174) 
     
≥ 50 309 122 227 (180-274) 1.60 
0 - 49 117 36 142(79-205) 
 
 
5.2.2. Effect of other baseline factors 
There were no statistically significant differences in gender or geographical areas with respect to 
baseline CD4 counts. Median baseline CD4 cell count for female (68.3%) was 118 (44-190) and 
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139 (33-152) for male patients; 107(39-177) and 109 (49-195) for Kampala (63.2%) and 
Mbarara, respectively. However, female patients demonstrated a faster CD4 increase and 
reached higher CD4 cell levels compared to male patients (p=0.0005). During the study we 
observed that absolute CD4 increase was faster among patients from Mbarara hospital (37.8%) 
compared to JCRC-Kampala (p=0.0107). 
 
 
5.3. VARIATION IN EFAVIRENZ PHARMACOKINETICS AND ITS EFFECTS OF 
ART RESPONSE; PAPERS 3-4 
 
5.3.1. Effect of HIV/AIDS on efavirenz pharmacokinetics; Paper 3 
When pharmacokinetic data from 29 HIV infected, ART naive Ugandans were compared with 
data from 32 healthy Ugandans, no differences were observed in demographic characteristics 
between the HIV positive and negative participants. Slight differences were observed in the 
frequency of CYP2B6 and CYP3A5*1 genotypes between the HIV positive and negative study 
groups, but these differences did not reach statistical significance. Using covariate analysis, HIV 
/AIDS was identified as a statistically significant categorical predictor of efavirenz 
pharmacokinetics and HIV/AIDS patients displayed 30% (95% CI 18.7- 40.7) lower relative 
bioavailability than healthy subjects. Gender was a secondary factor that influenced efavirenz 
pharmacokinetics with females having a 2-fold (95% CI 1.53- 2.63) higher volume of distribution 
of the peripheral compartment after oral administration (V2/F) than males. This increase in 
volume of distribution resulted in a 2-fold longer elimination half-life for females compared to 
males. 
 
 
5.3.2. Variation in efavirenz pharmacokinetics among ART naive 
Ugandans; Paper 4  
Data from 66 HIV positive, ART naive patients with complete pharmacokinetic profiles (9 data 
points over 24h) on days 1 and 14, showed great intra and intersubject variation in efavirenz 
concentrations and degree of autoinduction. The patients had normal biochemical results 
including liver and renal function tests results, mean weight was 51.7 kg (SD 9.2), average 
baseline CD4 cell count 249 cells/µl (SD 97) and baseline mean viral load of 107468 
copies/mL. The day 14 efavirenz plasma concentrations varied from an average of 2.9 µg/l 
(range 0.8–12.0) to 7.49 µg/l (range 3.0–19.4) for minimum (Cmin) and maximum (Cmax) 
concentrations respectively. The interindividual variations were also observed in the apparent 
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oral clearance of the drug with ranges of 1.6–20.6 l/h, and 1.9–16.4 l/h for days 1 and 14 
respectively. Although overall mean clearance did not change over the 2 weeks (mean 7.5l/h and 
7.4l/h, for days 1 and 14 respectively), 41.9% of participants showed an average 95.8% increase in 
clearance while no increase was observed in the other patients. On day 14, efavirenz Cmax was >4 
mg/mL in 96.6% of participants, while 4.5% of the patients had Cmin <1 mg/mL. 
 
The tendency of efavirenz to induce its own metabolism impacted on day14 drug concentrations. 
The mean values for the efavirenz Cmax and Cmins on day 14 were statistically lower in the group 
of patients who exhibited autoinduction (p=0.0085 and p=0.01, respectively). Among the 41.9% 
of the patients who exhibited autoinduction, there was a negative correlation between the degree 
of autoinduction and day 14 efavirenz Cmin, and hence, patients with greater degrees of 
autoinduction had lower day 14 Cmin compared to patients with a lower capacity of efavirenz 
autoinduction. No difference was observed in efavirenz pharmacokinetics among patients of 
different baseline CD4 cell counts. Surprisingly, we also observed a negative correlation 
between serum albumin level and efavirenz concentrations on day1, which could be another 
surrogate of HIV severity. This relation was however not maintained to day14 of treatment.  
 
 
5.3.3. Effect of variability in efavirenz pharmacokinetics on ART 
response; Paper 4 
Data on central nervous system (CNS) toxicity attributable to efavirenz treatment were available 
for 58 of the 66 patients, and among the reported symptoms were abnormal dreams/nightmares, 
insomnia, dizziness and headache. Of the 58 patients, 40(69%) reported symptoms related to 
CNS toxicity, and 38 (95%) of these had efavirenz plasma concentrations above the therapeutic 
range on day 14. The frequency of efavirenz-related CNS complaints that were graded as 
moderate to severe was higher among patients who maintained high efavirenz concentrations 
beyond 8 hour after the dose (Table 3).  
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Table 3: Day 14 efavirenz plasma concentrations and corresponding efavirenz-related central 
nervous system (CNS) adverse effects in 58 HIV-infected Ugandans during the first 2 weeks of 
treatment with efavirenz, lamivudine and zidovudine (Paper 4) 
 
Efavirenz plasma concentration 
after observed dosing on day 14 
 
Number of patients with 
moderate to severe 
(grade 2/3)* CNS 
symptoms 
Number of patients 
with mild (grade 1)* 
CNS symptoms 
Number of 
patients 
with no CNS 
symptoms 
Total number per 
efavirenz plasma 
concentration 
category 
> 4 µg/mL within 8h after dosing 
 
3 16 8 27 
> 4 µg/mL 8h after dosing 
 
5 14 8 27 
No plasma concentrations >4 
µg/mL 
0 2 2 4 
Total number of patients per 
CNS toxicity category 
8 32 18 58 
*Severity grading of efavirenz-related adverse CNS symptoms was based on the WHO toxicity table, where ‘mild 
symptoms (grade 1)’ are transient (<48 h) with no medical intervention required, ‘moderate symptoms (grade 2)’ 
have mild-to-moderate limitations in activity and no or minimal medical intervention is required, ‘severe symptoms 
(grade 3)’ have marked limitations in activity and medical intervention or hospitalization is required, and ‘grade 4’ 
is life-threatening. No life-threatening efavirenz-related adverse reactions were observed during the 2 weeks of the 
study 
 
 
5.4. VARIATION IN EFAVIRENZ PHARMACOGENETICS AND SUGGESTED DOSE 
MODIFICATIONS; PAPER 5 
 
Modelling and simulation of the pharmacokinetics and pharmacogenetics data for 99 (64 females) 
HIV infected patients showed CYP2B6*6 genotype to be a major predictor of exposure to 
efavirenz. Overall, the simulated mean AUC was 72523 Kg/L·h for the 600 mg dose for the 
Ugandan population, which is 1.25 fold times the mean AUC in the product label (58084 Kg/L·h). 
Subjects homozygous for CYP2B6 *6 mutation exhibited a mean AUC of 12 x 104 Kg/L·h, which 
is more than 2 times the mean AUC in the product label, and higher mean AUC was attained in 
CYP2B6 *6/*6 genotype compared to CYP2B6 *1/*1 (p< 0.0001). Mean AUC values for both 
wild type and heterozygous mutants were within the exposure range observed during clinical 
studies reported in the product label. These results are presented in figure 7.  While plasma 
efavirenz exposure differed significantly between CYP2B6*6 (*1/*1)/ homozygous wild type 
ABCB1 (c.4046A>G) and CYP2B6*6 (*6/*6) / mutant ABCB1 (c.4046A>G) (p<0.0001) no 
difference was observed between CYP2B6*6 (*6/*6) / mutant ABCB1 (c.4046A>G) and 
CYP2B6*6 (*6/*6) /homozygous wild type ABCB1 (c.4046A>G) p<0.53. Simulated exposures 
for EFV daily doses of 300mg for CYP2B6*6/*6 genotype, and 450mg for the Ugandan 
population; were found to be comparable to those for the product label (table 4). Efavirenz oral 
clearance was 2.2 and 1.7 fold higher in CYP2B6*6 (*1/*1) and CYP2B6*6 (*1/*6) compared 
CYP2B6*6 (*6/*6) carriers, while a 22% increase in F1 was observed for the mutant ABCB1 
c.4046A>G.  
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Figure 7: Distribution of estimated patients AUC values, stratified by CYP2B6 genotype. 
Groups 1, 2 and 3 represent patients with CYP2B6*1*6, CYP2B6*6/*6; and CYP2B6*1/*1 genotypes, 
respectively, while the transverse dotted line represents mean AUC for the product label. The estimated AUC of 
patients homozygous for the CYP2B6*6 mutation were higher than the mean for the product label 
 
 
Table 4: Simulation based AUC for 300, 450, and 600 mg doses in various genotype groups 
 
   Dose= 300mg daily Dose= 450mg daily Dose= 600mg daily 
   Area Under the curve (µg/L.h)x10
4
 
 CYP2B6*6 Number of 
observation
2
 
Mean  95% CI Mean  95% CI Mean  95% CI 
All participants  All 47000 3.63  1.57-7.58 5.44  2.35-11.06 7.25  3.14-14.75 
 
 
ABCB1 
(c4046A>G) wt 
*1/*1 17500 2.5  1.28-5.41 3.75  1.92-3.50 5.0  2.56-8.49 
*1/*6 2000 3.16  1.63-5.34 4.74  2.45-8.01 6.32  3.27-10.68 
*6/*6 10500 5.57  2.85-9.53 8.36  4.27-14.29 11.14  5.7-19.05 
ABCB1 
(c4046A>G) mut 
*1/*1 4000 3.20  1.65-5.41 4.80  2.48-8.11 6.41  3.31-10.81 
*1/*6 9000 4.05  2.10-7.05 6.07  3.14-10.58 8.10  4.19-14.10 
*6/*6 4000 7.12  3.63-12.20 10.67  5.45-18.30 14.23  7.26-24.40 
2 The frequency of each group in these simulations reflects the population frequency of the groups in the observed patients’ data 
The simulation based mean AUC for the 300mg dose in the CYP2B6*6/*6 genotype group and that for the 450mg dose in 
the entire Ugandan population were comparable to the mean AUC of 58084 Kg/L·h in the product label. 
 
 
Viral load fell precipitously on treatment with only six (6.1%) patients having HIV RNA > 40 
copies/mL after 84 days of treatment. No trend with exposure was noted for these six patients, and 
their AUC were found to be either within range or above the product label AUC, implying that 
baseline viral resistance might have played a role 
 
 36 
5.5. THE EFFECT OF VARIATION IN PHARMACOGENETICS ON EFAVIRENZ 
DRUG-DRUG INTERACTIONS; PAPER 6 
 
This dataset consisted of 263 HIV ART naïve patients, 60% (n =157) co-infected with TB, with 
efavirenz concentrations collected over 252 days.   The HIV, TB co-infected patients had lower 
average body weight than the HIV only group, 50.3kg versus 54.9 kg respectively (p<0.0001);  
lower mean baseline CD4 cell counts 88 versus  150 cells/µl (p<0.001); and lower mean albumin 
levels, 2.8 versus 3.9 g/dl’ p<0.001. CYP2B6*6 homozygous genotype was observed at 10% for 
the entire study population but 13.5% among the HIV/TB patients and at 7.3% among the HIV 
only group. 
 
5.5.1. Autoinduction during efavirenz-rifampicin co-treatment  
Overall, maximal enzyme induction was observed at day 168 in both treatment groups although 
slight differences were observed between the rifampicin and non-rifampicin co-treatment groups. 
HIV patients co-infected with TB received at least 2 weeks of rifampicin therapy before efavirenz 
treatment was initiated, and as result, these patients had significantly higher apparent oral 
efavirenz clearance compared to patients without rifampicin during early efavirenz therapy on day 
14 (p=0.03) but no effect was observed on day 56 or thereafter. Increasing efavirenz apparent oral 
clearance trends from day 14, peaking on day 168 and dropping back by day 224 were observed 
for all study participants (day 14: 12.65, day 168: 14.10 and day 224: 12.19).  
 
5.5.2. Effect of genotype 
Long-term induction was predicted by CYP2B6*6. Comparison of enzyme induction by 
CYP2B6*6 genotypes during efavirenz treatment alone and during efavirenz plus rifampicin 
treatment showed CYP2B6*1 carriers  to have exhibited enzyme induction in a gene dependant 
manner. Maximum difference over time was observed among CYP2B6*1/*1 followed by *1/*6 
while *6/*6 individuals exhibited no difference in clearance. Notably among CYP2B6*1/*1 
genotype, the effect of efavirenz auto-induction on its own long-term clearance was much higher 
when given alone than during rifampicin co-administration in (Fig. 8). 
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Figure 8: Comparison of efavirenz apparent oral clearance and plasma concentrations between 
"efavirenz only" and "efavirenz-rifampicin" treated patients, stratified by CYP2B6 genotype 
Full lines represent "Rifampicin co-treated" patients while dotted blue lines represent the “Efavirenz only" group. A 
paradoxical effect was observed with efavirenz apparent oral clearance being higher in “Efavirenz only” group with 
CYP2B6*1/*1genotype compared to the Rifampicin co-treated patients (upper graphs).  An increase in efavirenz 
plasma concentrations over time was observed among the CYP2B6*6/*6 genotype (lower graphs) 
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6. GENERAL DISCUSSION 
 
The thesis highlights population variations in CD4 cell reference values, which is the main 
immunological marker of HIV/ART progress in adults and adolescents. The magnitude and 
importance of variations in pharmacokinetics and pharmacogenetics of efavirenz, a key first line 
antiretroviral drug, are also highlighted.   
 
The first study (paper 1) demonstrated a wide reference range of 418-2105 CD4 cells/µL. The 
range presents a 5-fold variation in normal absolute CD4 cell values for the country. The reference 
range is also wider than what has been reported from most countries and regions [28, 29]. 
However, it is consistent with results from one of the previous studies in Uganda[32]. There are 
reports of faster CD4 cell deterioration among populations with higher CD4 cell counts [35, 36] 
and wide reference ranges such as the one reported in this thesis may place persons with high CD4 
cell values at risk of developing advanced HIV while waiting for treatment initiation at specific 
CD4 cell counts.  
 
Further still, sub study demonstrated variations in absolute CD4 cell counts with relation to socio-
demographics (paper 1). High altitude and the low socio-economic status of Mbarara participants 
were possible causes of their low CD4 cell reference values. However, low socio-economic status 
would have been associated with a low mean haemoglobin value but on the contrary, participants 
from Mbarara had significantly higher mean values for neutrophils and haemoglobin level (p 
values 0.001 and 0.003 for neutrophils and haemoglobin, respectively) compared to Kampala 
participants. It was therefore concluded that the observed regional difference in mean CD4 cell 
values was due to altitude. This observation is consistent with findings from other studies that 
reported haematological changes at high altitude including reduction in CD4/CD3 subsets; and 
increment in neutrophils and red blood cell component [24, 25]. Although the effect of socio-
economic status has previously only been investigated among HIV seropositive individuals, this 
thesis reports low CD4 cell counts among HIV seronegative individuals with lower income. Some 
of the factors that are frequent among persons at low socio-economic status, including 
malnutrition and frequent ailments, could partly be responsible for the low CD4 cell counts at low 
income [151, 152]. Research among HIV positive patients has demonstrated a higher relative risk 
of death or developing AIDS among HIV/ART patients with low income even when their baseline 
CD4 cell counts were comparable to the patients of higher income [153-155]. Findings from this 
study may indicate that effect of low income on immunity may be prevailing even before people 
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acquire HIV, and hence putting them at risk of poor HIV/ART outcomes that is reported in those 
studies [153-155]. The effect on parasitic and other viral infections in lowering CD4 cell counts 
among both HIV negative and positive patients has been reported [37, 39, 156-158]. The decision 
on when to initiate ART among HIV patients co-infected with acute illnesses gets complicated by 
the additional influence of the illnesses on CD4 cell values.  
 
In substudy II (paper 2), we observed a low median CD4 cell count for patients who started ART 
during the selected study period. We further observed a low proportion ( 37.1%) of patients who 
had complete immunological recovery compared to proportions reported from Europe, North 
America, and particularly from the Swiss cohort where only 1/3 of the patients had immunological 
failure[159]. Evidence from these studies indicates that the reduced capacity of immunological 
recovery observed in my study patients was caused by delayed initiation of ART [71, 72, 159, 
160]. This was further confirmed by the fact that the median CD4 cell counts for the 
immunological responders was higher than that of immunological failures, 142 (IQR 72-212) and 
86 (IQR 34-155), respectively. The bone marrow has been shown to have reduced haemopoetic 
potential during advanced HIV [11, 12] and there is evidence that HAART started as early as 
during primary HIV leads to faster and more complete immune reconstitution [79, 80, 161, 162]. 
In the light of these findings, early ART would preserve the haemopoetic potential of the bone 
marrow and hence lead to complete immunological recovery. 
 
Even though females have been reported to have higher CD4 cell reference values, and that there 
are reports of faster HIV progression among patients with higher CD4 cell reference values [32-
34, 36], it is interesting to note that we and other researchers [94, 95] observed better clinical and 
immunological response among female patients. There could be some inherent factors causing the 
female seronegative population to have higher CD4 counts and HIV/ART female patients to have 
faster immunological recovery. Regarding ART response by study region, we had expected 
Kampala participants to have a faster immunological recovery given a longer HIV/ART 
experience at JCRC (HIV/ART centre in Kampala) compared to Mbarara. It is difficult to 
understand why Mbarara participants showed a faster immunological recovery than Kampala 
patients in sub-study II yet lower CD4 reference values were observed for Mbarara healthy 
volunteers in sub-study I. This finding could have been due to a random effect or to reasons not 
well understood. However, given all these factors that influence CD4 reference values and CD4 
cell recovery, it is possible that waiting for all HIV positive patients to deteriorate to specified 
CD4 cut off values for treatment, may subject some patient populations to a risk of losing lose 
their immune-haemopoetic potential [11, 12].  Much earlier ART initiation during primary HIV, 
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or an approach of “test and treat” could lead to better HIV/ART outcomes including functional 
cure or preservation of the immune system until an opportunity of better approaches including 
inducing latency of the virus within the CD4 cells [79, 85-87, 90].  
 
In sub-study III (papers 3-6), we observed variability in efavirenz pharmacokinetics with 
HIV/AIDS, CYP2B6 genotype and gender being the predictors of efavirenz pharmacokinetics. 
Exploration of the effect of HIV/AIDS on efavirenz pharmacokinetics showed a 30% lower 
relative bioavailability of efavirenz among HIV infected individuals compared to healthy 
volunteers, after a single dose (paper 3). Similar finding of altered pharmacokinetics of drugs 
during HV/AIDS have been reported, including findings of lower plasma concentrations of 
atazanavir among HIV/AIDS patients compared to healthy volunteers [163] and reduced 
bioavailability of  zidovudine in advanced HIV/AIDS [59]. The reduced bioavailability of 
efavirenz, and other drugs may be related to HIV/AIDS inflammatory processes leading to 
functional impairment of the absorptive surface [55]. However, effects of other factors including 
changes in expression of P-glycoprotein and ABCB1 may be implicated. The reduced 
bioavailability of zidovudine have a link to a report of overexpression of the p-glycoprotein on 
CD4 cells of HIV infected persons, which caused reduced accumulation of zidovudine within the 
cells [57]. The p-glycoprotein expression was found to increase as HIV/AIDS advances [57]and 
this protein acts as an efflux pump for a number of antiretroviral drugs. Changes in P-glycoprotein 
expression is a possible explanation for the low bioavailability of efavirenz in my HIV/AIDS 
participants. This study was the first step to demonstrate the effect of HIV disease on 
pharmacokinetics of antiretroviral drugs.   
 
Further attempts to explore the effect of HIV/AIDS on pharmacokinetics of efavirenz at steady 
state by using 66 HIV infected patients with different baseline CD4 counts (paper 4) showed no 
associations between CD4 counts and efavirenz exposure. With reports of increasing expression 
of the p-glycoprotein in advancing HIV[57], we had expected to see a difference in the 
bioavailability of efavirenz between severely immunosuppressed and the less 
immunocompromised patients. However, patients in this study had a mean baseline CD4 count of 
249 cells/µl; SD 97, and this narrow spectrum of baseline CD4 cell counts cannot be used to 
make conclusions. The contradicting findings from these two papers (3 and 4) could also imply 
that the direct effect of HIV/AIDS on efavirenz bioavailability may be short lived. If the observed 
effect was indeed due to functional impairment of the absorptive surface which occurs in 
HIV/AIDS, the inflammation is likely to clear following treatment initiation resulting into early 
stabilisation of the absorptive surface. The quick restoration of the function of the absorptive 
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surface that follows treatment initiation could also account for the loss of the albumin influence on 
day 14 efavirenz concentrations compared to what was observed on day 1 of this study.    Paper 4, 
however, reports great variability in efavirenz concentrations and auto-induction capacity of the 
patients, and the vast majority (95%) of patients who reported central-nervous efavirenz toxicity 
had concentrations above therapeutic ranges. Studies have previously reported CNS toxicity 
among patients with high plasma concentrations [57, 97, 115, 164], but the proportion of patients 
with the CNS side effects observed in my study was relatively high, and this could be due to the 
high prevalence of CYP2B6*6 polymorphism in the African population [122, 126, 130].  
 
The differences in efavirenz concentrations and clearance related to the CYP2B6 genetic 
variability reported in papers 3-6 of this thesis have previously been documented [102, 113, 115, 
129]. Individuals who are homozygous for the CYP2B6*6 wild type have been reported to 
metabolise efavirenz much faster, and show greater tendencies of efavirenz to induce its own 
metabolism compared to persons with the mutation [96, 102, 115, 118, 119, 122, 128-130]. On the 
contrary, individuals homozygous for the mutation show less auto-induction, are slow 
metabolisers of efavirenz and tend to have high efavirenz concentrations compared to the persons 
without the mutation [115, 118, 119, 122, 130]. The high efavirenz plasma concentrations among 
the CYP2B6*6 group of patients has previously been correlated with high rates of efavirenz 
toxicity and discontinuation [103, 115]. Dosage modifications proposed earlier [165] and in this 
thesis may reduce the frequency of CNS toxicity in the African population. Findings reported in 
paper 4 are complimented with our findings in paper 6 where we observed a gene dependent 
increase in efavirenz clearance over time; greatest in CYP2B6*1/*1, followed by CYP2B6*1/*6, 
while the CYP2B6*6/*6 did not demonstrate any tendency to autoinduction. The patients who 
showed minimal tendencies of autoinduction and had high efavirenz concentrations in paper 4, are 
likely to have CYP2B6*6/*6 genotype. Pharmacogenetic- directed dosing of patients or patient 
populations has been suggested to reduce efavirenz-related toxicity [113].  
 
Our findings in paper 5 showed that using the current 600mg efavirenz dose, efavirenz exposure 
at steady state is anticipated to be twice as high for the CYP2B6*6/*6 genotype, predisposing 
these patients to adverse effects.  Further modelling of the data predicted efavirenz dosage 
adjustment of 300mg to achieve adequate exposure and pharmacodynamic effects for the 
CYP2B6*6/*6, while 450mg would achieve similar pharmacodynamic effects in the Ugandan 
population. These predictions are in line with previous findings: Nyakutira et al. predicted 35% 
dosage reduction for the Zimbabwean population to achieve adequate efavirenz plasma 
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concentrations [122], while Gatanaga et al. observed adequate viral suppression at 400mg 
among the CYP2B6*6/*6 carriers [165].   Consideration of these dosage reductions could reduce 
the efavirenz-related CNS toxicity in the African population, and especially the CYP2B6*6/*6 
carriers [100-103]. However, additional effects of prolonged CD4 cell increase has been 
documented among CYP2B6*6/*6 carriers following administration of 600mg of efavirenz, and it 
is not clear if this advantage would be maintained after the suggested dosage adjustments [96, 102, 
129].   
 
Our investigation of the implications of rifampicin co-treatment on the efavirenz plasma exposure 
in the Ugandan HIV patients showed that CYP2B6 genotype rather than rifampicin co-treatment 
explained the long-term effect of efavirenz autoinduction and plasma concentrations (paper 6). 
With the documented effect of rifampicin on inducing a number of enzymes that metabolise 
efavirenz, including CYP2B6, CYP2A6, CYP3A4, and UGT7B [141], we expected a reduction of 
efavirenz plasma concentrations over time, following rifampicin administration. We however 
noted that irrespective of rifampicin administration, patients with CYP2B6*1/*1 genotype had the 
highest increase in clearance resulting in reduced efavirenz concentrations over time, and that the 
clearance was higher when efavirenz was given alone compared to when it was co-administered 
with rifampicin.  There are similar reports from studies where the expected effect of rifampicin 
reducing efavirenz concentrations was not demonstrated when efavirenz  was co-administered 
with rifampicin based TB treatment[128, 141, 142]. There are even studies where a paradoxical 
increase in efavirenz concentrations was observed during rifampicin based TB-treatments [143]. 
Unlike when pharmacokinetics of efavirenz are studied with rifampicin given in isolation, 
antituberculous treatment often contain isoniazid and pyrazinamide, which have been shown to 
inhibit enzymes involved in efavirenz metabolism [139]. Isoniazid inhibits the CYP2A6 and 
CYP3A4 enzymes which play a significant metabolizing role at high efavirenz concentrations 
[113, 139, 140]. Also isoniazid, pyrazinamide and probably rifampicin were shown to inhibit the 
alternative pathways of 7-hydroxylation of efavirenz among the CYP2B6*1/*1 fast metabolisers, 
in addition to inhibition of CYP2A6 by both isoniazid and pyrazinamide [139]. High isoniazid 
concentrations such as those that occur in NAT2 slow acetylators were seen to greatly inhibit the 
7-hydoxylation in CYP2B6*6/*6, and this can cause paradoxical increase in efavirenz 
concentrations when co-administered with rifampicin-based TB therapy [139]. The impact of 
genetics on isoniazid metabolism is not well documented in most African populations, Uganda 
inclusive, but 68.7% of Ethiopian TB/HIV patients were reported as NAT2 slow acetylators [99]. 
The paradoxical increase in efavirenz concentrations during HAART-TB treatment that is 
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secondary to slow isoniazid metabolism may be wide spread in the African population, and 
regardless of rifampicin administration, genetic based efavirenz dose modification need to be 
considered.  
 
6.1. METHODOLOGICAL CONSIDERATIONS 
 
The study employed several methodological approaches and this was considered important in 
answering the different study objectives requiring different study populations and outcome 
measures. The study investigated the effect of a single exposure (HIV/AIDS) on two 
aspects/outcomes (pharmacokinetics and pharmacodynamics) of ART, with the specific 
measurements approached using different approaches. While a cross-sectional study approach 
adequately addressed the question of CD4 reference ranges, the rest of the research questions 
needed data that was collected over time.   
 
Investigating the effect of HIV/AIDS on efavirenz pharmacokinetics using different study 
populations revealed results that may have been missed if a single study population and design 
was employed. A single dose study showed HIV/AIDS patients to have a lower relative 
bioavailability compared to healthy volunteers and this finding would have been missed with a 
single prospective cohort of patients. Moreover the study in patients revealed no difference in 
pharmacokinetics of efavirenz at different disease severities, and this would have created an 
overall impression that HIV/AIDS has no effect on pharmacokinetics of efavirenz. Although still, 
we think that a sample comprising a wide range of baseline CD4 counts would have been more 
reliable to study the effect of HIV severity on efavirenz pharmacokinetics. This was not feasible 
with the current study since the investigator was not providing antiretroviral therapy but rather 
relied on patients deemed ready for ART under the national programme and hence had no control 
on patients’ baseline characteristics. 
 
A longitudinal study design with a prospective cohort would have been the best approach for sub-
study II investigating the effect of HIV severity on ART outcomes. However, it would have been 
difficult to obtain a sufficient simple size within the available time and related resources. For that 
matter, a retrospective data review was considered despite the challenges of documentation and 
data storage in low resource settings. Moreover, the data not routinely collected in low resource 
settings including viral load assays, could have affected interpretation of results.  Findings from 
this study however, provide valid evidences comparable to operational research findings using 
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data collected from HIV/ART files used in routine practice. This provides good evidence of the 
outcomes from a day to day operation of HIV/ART clinical practice.  
 
The short prospective pharmacokinetic study yielded clinical data over a period of 8 months. 
Although this clinical data was utilised in the pharmacokinetics-pharmacodynamics data reported 
in paper 5, the period may not be sufficient to make strong clinical judgements.  
 
In the pharmacogenetic studies it would have been interesting to include participants from 
additional regions, especially the Nilotic group in northern Uganda, for purposes of capturing the 
different genetic representation of the country. However, prevailing circumstances including 
financial constraints, accessibility and previous security issues caused exclusion of the region. The 
populations included in the study may not give good genetic representation of the country, but 
does give a picture of the importance of pharmacogenetic variations within the country. 
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7. CONCLUSIONS AND RECOMMENDATIONS 
 
7.1. GENERAL CONCLUSION 
 
Just as the virus and host-cell characteristics vary and affect HIV/ART outcomes, variations in 
relevant baseline characteristics including CD4 cell values and pharmacogenetics, influence 
HIV/ART outcomes.  My study population varied greatly in CD4 cell reference values, and pre-
treatment CD4 cell counts affected immunological recovery. CYP2B6*6 genotype influenced 
efavirenz pharmacokinetics, and a high proportion of HIV infected Ugandans exhibited high 
efavirenz plasma levels and central nervous adverse effects. Given the great diversity observed 
among Africans, the impact of these un-addressed factors could be implicatory in HIV/ART 
outcomes in sub Saharan Africa. 
 
 
7.2. RECOMMENDATIONS 
7.2.1. Recommendations for findings in sub-studies I and II 
 My study shows the value of early ART initiation. Approaches including the “test and treat”, or 
“ART initiation during primary HIV infection” should be considered.  The approaches would 
address the current challenge of optimal timing for antiretroviral treatment, and could have added 
advantages including functional cure for some HIV infected patients. Setting CD4 cell limits for 
treatment initiation may not be addressing all the challenges related to population variations in 
CD4 cell values, thus putting some HIV infected patients at risk of delayed treatment.  
 
7.2.2. Recommendations for findings in sub-study III 
Efavirenz is a widely used antiretroviral drug, including among patients co-infected with TB, 
malaria and hepatitis, due to its relatively low cost and high efficacy. Population and 
pharmacogenetics based dosing is recommended, including the suggested 450 mg dose for an 
African population, and 300mg dose for the CYP2B6*6/*6 genotype, that are suggested in this 
thesis. The dosing should be in the light of reducing efavirenz related adverse effects and at the 
same time maintaining the efficacy advantages previously observed among the CYP2B6*6/*6 
genotype.  
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